Directs deal sourcing and operational due diligence across technology and healthcare buyouts, allocating capital into companies undergoing digital transformation and operational scale-ups. Stephen Dodson brings investment committee experience in structuring growth equity and control transactions, alongside portfolio operational roles that drove margin expansion and revenue acceleration. Prior roles span principal-level investing and corporate strategy; education includes an MBA and undergraduate degree in economics. Market relevance centers on deal origination in North America and hands-on portfolio value creation for institutional LPs.
Directs deal sourcing and operational due diligence across technology and healthcare buyouts, allocating capital into companies undergoing digital transformation and operational scale-ups. Stephen Dodson brings investment committee experience in structuring growth equity and control transactions, alongside portfolio operational roles that drove margin expansion and revenue acceleration. Prior roles span principal-level investing and corporate strategy; education includes an MBA and undergraduate degree in economics. Market relevance centers on deal origination in North America and hands-on portfolio value creation for institutional LPs.
Focuses on growth-oriented control and structured growth equity investments in technology and healthcare businesses undergoing digital transformation and operational scale-ups. Prefers North American mid-market companies where active governance, KPIs-driven operational playbooks, and selective add-on M&A accelerate revenue and margin expansion. Capital allocation favors staged commitments tied to operational milestones, with a 3–7 year value-creation horizon and disciplined downside protection via covenants and governance rights. Investment decisions combine thematic sector research, rigorous operational due diligence, and hands-on portfolio interventions to de-risk execution and drive exit optionality.
Focuses on growth-oriented control and structured growth equity investments in technology and healthcare businesses undergoing digital transformation and operational scale-ups. Prefers North American mid-market companies where active governance, KPIs-driven operational playbooks, and selective add-on M&A accelerate revenue and margin expansion. Capital allocation favors staged commitments tied to operational milestones, with a 3–7 year value-creation horizon and disciplined downside protection via covenants and governance rights. Investment decisions combine thematic sector research, rigorous operational due diligence, and hands-on portfolio interventions to de-risk execution and drive exit optionality.
| Trades 28 | Longs Won 11/28 39% | Profit Factor 1.63 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $2.42M |
| Average Win $1.94M | Best Trade (May 18) $13.45M | Sharpe Ratio -74.98 |
| Average Loss -$770,951.1 | Worst Trade (May 15) -$2.97M | Z-Score -0.75 (54.74%) |
| Commissions $0 | Avg. Trade Length 1y 4m 2w 3d | Expectancy $295,866.72 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | 0.03% | 0.25% | 1.53% | 7.33% | 29.11% |
| Consecutive Losing Trades | 152 | 136 | 121 | 106 | 91 | 76 | 61 | 45 | 30 | 15 |